Zevra Therapeutics is developing ACER-002 (celiprolol) tablets for the treatment of vEDS in people with a COL3A1 variant to reduce the risk of arterial and other hollow organ clinical events.
“Vascular Ehlers-Danlos syndrome (vEDS) is a life-threatening rare disease, which is why Zevra Therapeutics is committed to bringing a new treatment to the vEDS community. Through our Decentralized Study Evaluating Celiprolol on VEDS Related Events (DiSCOVER) clinical trial, we are investigating celiprolol as a potential therapy for VEDS. Want to know if you’re eligible? Learn more about our DiSCOVER trial and enroll here.”
View the clinical trial information factsheet here.
